Видео ютуба по тегу Ceo Syngene

Biosimilar Growth Is Offsetting Decline In Syngene & Generics: Biocon | CNBC TV18
Biosimilar Growth Is Offsetting Decline In Syngene & Generics: Biocon | CNBC TV18
Syngene International Earnings Call - Q2 FY25
Syngene International Earnings Call - Q2 FY25
Syngene International Ltd Q2 FY2024-25 Earnings Conference Call
Syngene International Ltd Q2 FY2024-25 Earnings Conference Call
Syngene International Q2: Profit Shrinks & Margins Narrow, CEO Jonathan Hunt On Growth Outlook
Syngene International Q2: Profit Shrinks & Margins Narrow, CEO Jonathan Hunt On Growth Outlook
Syngene International Earnings Call for Q2FY25
Syngene International Earnings Call for Q2FY25
Syngene International In-Line Q2 Result: Key Growth Drivers, Margin Guidance Ahead | Jonathan Hunt
Syngene International In-Line Q2 Result: Key Growth Drivers, Margin Guidance Ahead | Jonathan Hunt
EXCLUSIVE: Jonathan Hunt On Q2 Numbers, Pharma Sector And Growth Plans For FY25
EXCLUSIVE: Jonathan Hunt On Q2 Numbers, Pharma Sector And Growth Plans For FY25
What Impact Will the Biosure Act Have on the Future of the Indian CRDMO Sector? | Stock Market
What Impact Will the Biosure Act Have on the Future of the Indian CRDMO Sector? | Stock Market
Syngene Q1 Earnings: In-Line Profits Recorded, What's The Growth Outlook Of Company In Future?
Syngene Q1 Earnings: In-Line Profits Recorded, What's The Growth Outlook Of Company In Future?
'Got Super Modern Laboratories In India': Syngene International MD & CEO
'Got Super Modern Laboratories In India': Syngene International MD & CEO
Expect New Capital To Begin Creating Demand In The Biotech Segment In H2: Syngene International
Expect New Capital To Begin Creating Demand In The Biotech Segment In H2: Syngene International
Syngene International Q1 Results: Profit Falls 19%, Maintains FY25 Guidance
Syngene International Q1 Results: Profit Falls 19%, Maintains FY25 Guidance
Overcoming CEO succession planning obstacles
Overcoming CEO succession planning obstacles
Syngene's MD and CEO, Jonathan Hunt, on Q4 and FY24 results
Syngene's MD and CEO, Jonathan Hunt, on Q4 and FY24 results
Syngene: FY25 Capex Expansion Plans, Expecting PAT To Grow In Single Digit | Jonathan Hunt | ET Now
Syngene: FY25 Capex Expansion Plans, Expecting PAT To Grow In Single Digit | Jonathan Hunt | ET Now
High Single Digit To Low Double Digits Revenue Projections For FY 25: Syngene International CEO
High Single Digit To Low Double Digits Revenue Projections For FY 25: Syngene International CEO
Focus Is On US Startups In The Biotech Industry, New Capacities To Come On Board In H2FY25: Syngene
Focus Is On US Startups In The Biotech Industry, New Capacities To Come On Board In H2FY25: Syngene
DCAT Week 2024 ROB HAXTON, Vice President integration Lead at Syngene International
DCAT Week 2024 ROB HAXTON, Vice President integration Lead at Syngene International
Syngene International Q3 Fineprint, Capex Focus & FY25 Growth Drivers | Jonathan Hunt
Syngene International Q3 Fineprint, Capex Focus & FY25 Growth Drivers | Jonathan Hunt
Earnings Edge | Syngene's Jonathan Hunt On Q3 Performance | NDTV Profit
Earnings Edge | Syngene's Jonathan Hunt On Q3 Performance | NDTV Profit